Malignant glioma represents one of the most aggressive and lethal human neoplasias. A hallmark of gliomas is their rapid proliferation and destruction of vital brain tissue, a process in which excessive glutamate release by glioma cells takes center stage. Pharmacologic antagonism with glutamate signaling through ionotropic glutamate receptors attenuates glioma progression in vivo, indicating that glutamate release by glioma cells is a prerequisite for rapid glioma growth. Glutamate has been suggested to promote glioma cell proliferation in an autocrine or paracrine manner, in particular by activation of the (RS)-a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid hydrate (AMPA) subtype of glutamate receptors. Here, we dissect the effects of glutamate secretion on glioma progression. Glioma cells release glutamate through the amino-acid antiporter system X c À , a process that is mechanistically linked with cystine incorporation. We show that disrupting glutamate secretion by interfering with the system X c À activity attenuates glioma cell proliferation solely cystine dependently, whereas glutamate itself does not augment glioma cell growth in vitro. Neither AMPA receptor agonism nor antagonism affects glioma growth in vitro. On a molecular level, AMPA insensitivity is concordant with a pronounced transcriptional downregulation of AMPA receptor subunits or overexpression of the fully edited GluR2 subunit, both of which block receptor activity. Strikingly, AMPA receptor inhibition in tumorimplanted brain slices resulted in markedly reduced tumor progression associated with alleviated neuronal cell death, suggesting that the ability of glutamate to promote glioma progression strictly requires the tumor microenvironment. Concerning a potential pharmacotherapy, targeting system X c À activity disrupts two major pathophysiological properties of glioma cells, that is, the induction of excitotoxic neuronal cell death and incorporation of cystine required for rapid proliferation.
Introduction
Gliomas are the most common primary tumors in the central nervous system derived from glial cells or glial progenitors, with glioblastomas as the most malignant entity (DeAngelis, 2001; Furnari et al., 2007) . Despite multimodal therapy regimens including neurosurgical resection, radiotherapy and cytotoxic chemotherapy, the prognosis of glioma patients remains poor, that is, o3% of patients survive more than 5 years (Ohgaki and Kleihues, 2005) . Rapid proliferation, diffuse brain invasion as well as tumor-induced brain edema and neurodegeneration are pathological hallmarks of these tumors and are likely to determine unfavorable prognosis (Savaskan et al., 2008) .
Numerous studies showed that glioma cells secrete high levels of the neurotransmitter glutamate, resulting in neuronal cell death Behrens et al., 2000; Savaskan et al., 2008; Marcus et al., 2010 ) and brain edema (Savaskan et al., 2008) through excitatory activation of neuronal glutamate receptors. Glutamate receptor antagonists block neuronal degeneration in the tumor vicinity and lessen glioma growth in vivo, suggesting that neurodegeneration is a prerequisite for rapid glioma progression (Takano et al., 2001) . Excessive glutamate release by glioma cells has been linked to decreased activities of glial glutamate transporters such as EAAT1 (GLAST, SLC1A3) and EAAT2 (GLT-1, SLC1A2), resulting in decreased glutamate incorporation and consequently reduced extracellular glutamate clearance. In addition, the antiporter system X c À , mediating glutamate release in exchange for cystine, is abundantly expressed in glioblastoma specimens and cell lines Lyons et al., 2007; Savaskan et al., 2008 Savaskan et al., , 2009 . As a result, reduced EAAT1 and EAAT2 expression and concurrently abundant system X c À activity result in a net balance shifted toward glutamate release, thus promoting glioma progression. In line with these findings, enhancing EAAT2 expression in grafted C6 rat glioma cells reduced tumor size and elevated the life span of tumor-bearing animals (Vanhoutte et al., 2009) . Moreover, inhibition of glutamate release via system X c À , consisting of xCT (SLC7A11) and CD98 (SLC3A2, 4F2HC), profoundly decelerates the glioma phenotype in vivo (Chung et al., 2005; Lyons et al., 2007; Savaskan et al., 2008) and in addition mitigates tumor-induced brain swelling (Savaskan et al., 2008) . Even though the glioma-promoting properties of glutamate release by glioma cells appear to be without doubt, the underlying mechanisms are still poorly understood. Besides neurotoxic effects, some studies assume that extracellular glutamate promotes glioma proliferation in an autocrine or paracrine manner by activation of ionotropic glutamate receptors on gliomas, especially of the (RS)-a-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid hydrate (AMPA) subtype (Ishiuchi et al., 2002) .
The ionotropic glutamate receptor family comprises the AMPA, kainate and NMDA receptors, which mediate most excitatory neurotransmission in the central nervous system and function by opening a transmembrane ion channel on binding of glutamate (Lu et al., 2009) . The AMPA receptor subfamily forms functional heterotetramers composed of four types of subunits, designated GluR1 (GRIA1), GluR2 (GRIA2), GluR3 (GRIA3) and GluR4 (GRIA4), whereas the AMPA receptor activity is largely dependent on the AMPA receptor composition and in particular on the presence and processing of the GluR2 subunit. For example, alternative splicing of GluR2 transcripts generates 'flip' and 'flop' splice variants, with distinct desensitization kinetics . In addition, GluR2 transcripts undergo RNA editing at the Q/R site, resulting in a glutamine-to-arginine substitution that substantially reduces its Ca 2 þ permeability (Lomeli et al., 1994) . The GluR2 editing is 99.9% effective, so most GluR2-containing AMPA receptors do not flux Ca 2 þ . Several studies suggest that AMPA receptor signaling augments glioma cell proliferation in vitro. For example, GluR2 underediting at the Q/R site has been described in glioma specimen and cell lines, suggesting that glioma cells express Ca 2 þ permeable AMPA receptors (Maas et al., 2001) . GluR1 knockdown decreases glioma cell proliferation, which is associated with G 1 cell-cycle arrest in vitro (de Groot et al., 2008) . Moreover, adenoviral-mediated delivery of edited and thus Ca 2 þ impermeable GluR2 into CGNH-89 glioma cells impaired their proliferative activity and increased apoptosis. Conversely, overexpression of the unedited, Ca 2 þ permeable GluR2(Q) subunit augmented CGNH-89 glioma cell proliferation (Ishiuchi et al., 2002) . In clear contrast to these studies, it has been recently suggested that glioma cells survive glutamate-rich, excitotoxic environment due to intrinsic glutamate receptor inactivation, which is supported by the finding that GluR subunits are transcriptionally downregulated in glioma specimens (van Vuurden et al., 2009). Owing to this caveat and the apparent importance of glutamate signaling for potential glioma therapy, we analyzed in detail the effects of genetic and pharmaco logical interference with glutamate secretion and cystine incorporation mediated by system X c À as well as glutamate receptor agonism and antagonism on glioma growth in vitro and ex vivo. We show that neither glutamate nor AMPA possesses any mitogenic effects on glioma cells even under growth factor-reduced or low-cystine conditions. However, disrupting glutamate secretion by interfering with system X c À activity attenuates glioma cell proliferation, which is because of impaired cystine incorporation required for glutathione synthesis (Jones et al., 2004; Chung et al., 2005) and not because of decreased extracellular levels of glutamate. All glioma cell lines investigated appear to be insensitive to AMPA receptormediated signaling either by solid downregulation of all AMPA receptor subunits or disproportionately high expression of the fully edited GluR2 subunit, which blocks Ca 2 þ permeability of the AMPA receptor complex. In line with these findings, AMPA receptor antagonism did not affect glioma cell proliferation in vitro. In contrast, AMPA receptor inhibition in the tumor microenvironment alleviated neuronal cell death and profoundly reduced tumor growth, revealing a pronounced interrelation of tumorinduced neuronal cell death and glioma progression.
Results
Effects of glutamate and AMPA on glioma cell proliferation We initially investigated the effects of glutamate and AMPA application on glioma cell proliferation. Using six well-established glioma cell lines derived from rat (F98, C6), mouse (SMA-560, GL-261) and human (U87-MG, U373-MG), it was found that neither the application of glutamate (0.1-10 mM) nor AMPA (1-200 mM) enhanced glioma cell growth using standard culture conditions (glutamate-free medium supplemented with 10% fetal calf serum (FCS); Figures 1a and b) . In contrast, high doses of glutamate (5, 10 mM), but not AMPA, inhibited F98, C6, SMA-560 and GL-261 proliferation in a dosedependent manner (Figure 1b ). However, in some studies, promotion of glioma cell growth by glutamate was observed solely under serum deprivation (Yoshida et al., 2006) . Thus comparing with standard serum conditions, serum deprivation (glutamate-free medium supplemented with 0.5% FCS) resulted in a significant decrease in proliferation of F98, C6, SMA-560 and GL-261 cells (Figures 1c and d) . However, even under serum-deprived conditions neither the application of glutamate nor AMPA significantly rescued or increased glioma cell proliferation (Figures 1c and d) .
Targeted xCT inhibition reveals an essential role for cystine but not for glutamate in glioma cell proliferation On the basis of these findings, one might speculate that glioma cells release glutamate levels that are already sufficient to maintain high proliferation rates. Thus, we analyzed glioma cells (F98) in which xCT, the catalytic subunit of the glutamate-cystine antiporter system X c À , was knocked down by RNA interference, resulting in a pronounced reduction of glutamate secretion (Figure 2a) . Interestingly, inhibition of glutamate release by xCT knockdown (pS-xCT) did not affect glioma cell proliferation compared with control-transfected glioma cells (pS-con) under standard conditions. Moreover, the application of glutamate or AMPA did not augment proliferation when pS-xCT or pS-con glioma cells were grown in the presence of 10% FCS (Figure 2d ). Consistent with previous results (Figures 1c and d) , proliferation rates dropped when pS-xCT or pS-con glioma cells were challenged by serum deprivation (Figure 2b ). Interestingly, xCT knockdown resulted in a significantly more pronounced decline in proliferation compared with control-transfected glioma cells under these conditions (Po0.0001, t-test; Figure 2b ). These data imply that the activity of the glutamate-cystine antiporter system X c À indeed affects glioma cell proliferation, suggesting a role of either glutamate secretion or cystine incorporation in glioma growth. In contrast to the hypothesis that glutamate triggers glioma cell proliferation in vitro, the application of glutamate or AMPA did not rescue the specific decline in glioma cell proliferation induced by xCT knockdown observed under serum deprivation (Figure 2e ). Thus, we hypothesized that growth reduction mediated by xCT knockdown is because of a decrease in cystine incorporation rather than impaired glutamate signaling. In line with this hypothesis, application of cystine to the cell culture medium fully rescued the growth defect induced by xCT knockdown observed under serum deprivation (Figure 2c ). This indicates a direct role of cystine incorporation for glioma proliferation in vitro rather than glutamate secretion in this process.
Subsequently, we analyzed the effects of (S)-4CPG, a competitive small molecule inhibitor targeting system X c À activity and thus glutamate release Patel et al., 2004; Savaskan et al., 2008) . As suggested, the ability of (S)-4CPG to reduce F98 glioma cell growth (using medium containing 10% FCS) is essentially dependent on the concentrations of extracellular cystine (Figure 3a) . In the presence of 20 or 50 mM cystine, low micromolar doses of (S)-4CPG (IC 50(20 mM cystine) :1.8 mM, IC 50(50 mM cystine) :3.1 mM) reduced F98 glioma cell growth by 50%, whereas 460fold higher doses (IC 50(200 mM cystine) :163 mM) were required to achieve the same effect in the presence of 200 mM cystine (comparable to standard medium concentrations of cystine, 201 mM). In all cell lines investigated, 200 mM doses of (S)-4CPG impaired glioma cell growth in the presence of low cystine doses (20 mM), whereas higher cystine concentrations rescued this effect ( Figure 3b ). In contrast, neither glutamate nor AMPA was sufficient to rescue the growth-inhibitory effect of (S)-4CPG (200 mM) in the presence of 200 mM cystine ( Figures 3c and d) . A similar, cystine-dependent decrease in glioma cell growth was observed using sulfasalazine (SAS), a competitive and less selective small molecule counteracting system X c À activity (Lyons et al., 2007) . In all glioma cell lines investigated in this study, 200 mM SAS significantly reduced glioma cell growth in the presence of 20 or 50 mM concentrations of cystine, whereas higher cystine concentrations (200, 1000 mM) rescued this effect (data not shown).
Mechanisms of AMPA receptor inactivation in glioma cells
Because neither the application of glutamate nor AMPA affects glioma cell proliferation in various experimental settings, one might doubt the presence of active AMPA receptors in glioma cells. As AMPA receptor activity is largely dependent on the AMPA receptor composition and in particular the presence and processing of the GluR2 subunit, we initially characterized GluR1-GluR4 expression levels. Generally, GluR1 transcripts were not or barely detected in all glioma cell lines investigated, whereas glioma cells predominantly express either GluR3/4 (SMA-560, U87-MG) or GluR2/3/4 subunits (F98, C6, U373-MG) ( Figure 4a ). Relative to GluR1-GluR4 expression in primary astrocytes, quantitative analysis of GluR1-GluR4 transcript levels revealed the AMPA receptor subunits to be substantially downregulated in SMA-560, U87-MG and U373-MG glioma cells (Figure 4a ), which might explain their lack of glutamate/AMPA responsiveness. A recent study revealed a complete lack of inward current in U87-MG cells following glutamate treatment, supporting this hypothesis (van Vuurden et al., 2009) . In contrast, the transcript levels of GluR2 and GluR3 were severely increased in rat F98 and C6 glioma cells in comparison to primary astrocytes. In particular, the presence of the edited GluR2 subunit within the AMPA receptor complex blocks AMPA receptor signaling, whereas the unedited GluR2 subunit does not (Brusa et al., 1995) . Thus, we determined the GluR2 processing in F98 and C6 glioma cells with two independent restriction assays. In both cell lines, GluR2 transcripts underwent proper flip/flop alternative splicing at levels comparable to brain tissue and primary astrocytes (Figure 4b) . However, we were not able to detect unedited GluR2 transcripts in two well-established restriction site assays (Figure 4c ). To further unambiguously prove the findings on Q/R editing of GluR2 transcripts, we used the pyrosequencing technique allowing exact quantification. Again, GluR2 underediting was identified neither in F98 and C6 glioma cells nor in normal brain and primary astrocytes (Figure 4d) . Thus, the high expression of a fully edited GluR2 subunit may explain that proliferation of F98 and C6 glioma cells is not affected by AMPA or glutamate application. Taken together, our findings suggest that glioma cells are desensitized against AMPA receptor signaling either through AMPA receptor subunit downregulation or through overexpression of fully edited GluR2.
Glutamate receptor antagonism does not affect glioma cell proliferation in vitro In an inverse approach targeting glutamate signaling, we investigated the effects of ionotropic glutamate receptor antagonists on glioma cell growth using ZK 200775 (10 mM, competitive inhibitor) and GYKI 52466 (80 mM, noncompetitive inhibitor). Both antagonists show high affinities for AMPA receptors (ZK 200775 IC 50 : 0.12 mM;GYKI 52466 IC 50 :11 mM) and considerably lower affinities for kainate-and/or NMDA-type glutamate receptors (Donevan and Rogawski, 1993; Turski et al., 1998) . Occasionally, both antagonists moderately decreased glioma cell proliferation reaching levels of significance (Supplementary Figure 1A) . However, co-treatment with excessive doses of AMPA (200 mM) or glutamate (1 mM) did not rescue the moderate effects Figure 1C) . Similar results were obtained using selective, noncompetitive NMDA receptor antagonists (Norketamine, 10 mM; MK-801, 100 mM; data not shown). In summary, pharmacologic inhibition of ionotropic glutamate receptors did not affect glioma cell growth in vitro even at concentrations that exceed doses that give maximal effects in neurons.
AMPA receptor inhibition impedes neurodegeneration and glioma progression in the organotypic tumor microenvironment
To investigate to what extent interference with AMPA receptor activity affects glioma progression in an organotypic in vivo like environment, we monitored glioma progression using hippocampal brain slice cultures derived from rat. Following implantation of enhanced green fluorescent protein (eGFP)-labeled F98 rat glioma cells into the cortex, rapid and progressive tumor growth was observed at day 3 (242 ± 32%) and day 5 after implantation (DAI 5) (570±108%) compared with the tumor volume at day 1 after implantation (DAI 1) that was set to 100% (Figures 5a and b) . At DAI 5, tumor growth was associated with significantly increased propidium iodide (PI) uptake (red signal) into the brain parenchyma compared with control brain tissue not subjected to glioma cell implantation (Figures 5b and c) . Subsequent immunohistochemical analyses revealed that PI signal localization is restricted to neuronal nuclei as shown by NeuN staining, indicating neuronal cell death (Figure 5d ). Interestingly, treatment of tumor-implanted brain parenchyma with either GYKI 52466 (80 mM) or ZK 200775 (10 mM), significantly decreased tumorinduced neurotoxicity (Figures 5b and c) , which is associated with profoundly reduced glioma progression (Figure 5a ). Although the tumor volume at DAI 5 increased approximately sixfold in solvent-treated control brain slices (570 ± 108%), tumor progression was more than halved in brain tissue treated with GYKI 52466 (207±11%, Po0.01) or ZK 200775 (221±17%, Po0.01). Thus, when comparing tumor growth over time in brain slice cultures, application of both AMPA receptor antagonists, GYKI 52466 and ZK 200775, revealed mitigated tumor volume compared with untreated controls (Figure 5 ), indicating that AMPA receptor interference in tumor microenvironment possesses further antitumor effects that were underrepresented in solely single tumor cell cultures.
Discussion
This study was motivated by accumulating data showing that gliomas create a specific tumor microenvironment by excessive glutamate secretion into the extracellular space Takano et al., 2001; Savaskan et al., 2008) . Excessive accumulation of extracellular glutamate can cause excitotoxic neuronal degeneration and is implicated in the formation of brain edema and rapid glioma progression (Savaskan et al., 2008; Marcus et al., 2010) . Hence, glioma-borne glutamate has also been assumed as an autocrine factor mediating AMPA receptor-dependent glioma cell proliferation and growth. Previous studies revealed that glutamate release by glioma cells is mechanistically linked with cystine incorporation through system X c À activity. Thus, we expected that inhibition of glutamate release by system X c À activity may cause decreased overall glioma cell proliferation due to reduced glutamate receptor activation. Although we confirm glutamate as an important player in glioma progression, our data revealed that the propensity of glutamate to foster glioma progression ex vivo is rather indirect. Genetic or pharmacologic interference with glutamate secretion by targeting system X c À activity impedes glioma cell proliferation solely due to diminished cystine incorporation and not due to diminished glutamate release. This suggests that extracellular glutamate is dispensable for glioma cell proliferation in vitro. In contrast to the supposed growth-promoting activity of glutamate, we show that excessive glutamate concentrations (10 mM) significantly decreased the proliferation of F98, C6, SMA-560 and GL-261 glioma cells by more than 50%. A previous study demonstrated that system X c À activity is impaired in the presence of excessive doses of extracellular glutamate, resulting in reduced cystine uptake (Mawatari et al., 1996) . Thus, we examined whether the observed growth inhibition in the presence of high doses of glutamate might be rescued by increased cystine concentrations. Indeed, 400-800 mM doses of cystine fully abolished the growth-inhibitory activity of 10 mM glutamate observed under standard cell culture conditions (medium containing 201 mM cystine; data not shown). Besides excessive doses of glutamate, glioma cell proliferation in vitro appears to be unaffected by glutamate receptor agonists or antagonists, indicating that glioma cells are insensitive to excitotoxic or growthpromoting effects of glutamate mediated by glutamate receptor signaling. On a molecular level, insensitivity against AMPA receptor-mediated glutamate signaling is concordant with either a pronounced transcriptional downregulation of AMPA receptor subunits (SMA-560, U87-MG, U373-MG) or an overexpression of the fully edited GluR2 subunit (F98, C6). However, it remains elusive which mechanism may apply to human primary gliomas. By using the ONCOMINE data-mining platform (Rhodes et al., 2004) , it has been shown that GluR1-GluR4 transcript levels are significantly downregulated in a large number of glioma specimens compared with brain tissue samples . Using the same paradigm, reanalysis confirmed these results and in addition cornichon homologue 2 (CNIH2), a protein that has been recently shown to promote surface expression of AMPA receptors (Schwenk et al., 2009 ), appears to be significantly downregulated on transcript levels in a series of 81 glioma specimens compared with 23 brain samples (P ¼ 5.24
À10
). These data indicate impaired AMPA receptor activity in human glioma specimens and glioma cell lines. Taken together, our studies reveal that glutamate itself does not augment glioma cell proliferation in an autocrine or paracrine manner. However, the common hypothesis that glutamate triggers glioma proliferation might have been deduced from the beneficial effects of glutamate receptor antagonists in vivo. In line with this, AMPA receptor inhibition in brain tissue leads to alleviated neuronal cell death associated with markedly reduced tumor progression ( Figure 5 ). With this finding and the lack of in vitro efficacy on glioma cells in mind, one mechanistic explanation is that impaired tissue integrity due to neuronal cell death promotes tumor progression simply by creating space for glioma cell infiltration and growth. Another likely scenario is that damaged neurons release yet unknown factors that augment glioma cell proliferation.
As to potential glioma therapy, system X c À emerges as a promising target (Chung et al., 2005; Savaskan et al., 2008; Chung and Sontheimer, 2009; Pham et al., 2010) . Both components of system X c À (xCT and CD98) have shown to be transcriptionally upregulated in glioma specimens and interference with system X c À may disrupt two major pathophysiological properties of glioma cells: (1) the ability to induce neurodegeneration and (2) the ability to incorporate high levels of cystine required for rapid proliferation. Although glioma cells appear to be highly dependent on system X c À -mediated cystine incorporation required for glutathione production and thus the scavenging of reactive oxygen species (Chung et al., 2005; Chung and Sontheimer, 2009; Pham et al., 2010) , normal cells might be less vulnerable. This notion is supported by genetic deletion studies, that is, xCT-deficient mice are healthy in appearance and fertile (Sato et al., 2005; Shih et al., 2006; Liu et al., 2007) . Moreover, resistance of tumor cells to a variety of anticancer drugs is often associated with increased glutathione levels (Huang et al., 2005) . Hence, interference with system X c À activity may sensitize glioma and other neoplastic cells for drug treatment as shown for Hsp90 inhibitors (Huang et al., 2005; Pham et al., 2010) . In line with these findings, xCT knockdown reduced glioma cell proliferation solely under serum-deprived conditions (Figures 2b and c) , suggesting that reduced cystine incorporation sensitize glioma cells to further oxidative stress caused by serum deprivation (Zhuge and Cederbaum, 2006) . Notwithstanding promising preclinical data, a recent phase 1/2 clinical trial urges to exert cautiousness using currently available X c À inhibitors for glioma therapy (Robe et al., 2009) . In glioma patients, the application of SAS was associated with grade 4 toxicities as well as unfavorable MRI changes and thus the study was terminated after its interim analysis. Given the fact that the activity of SAS is not restricted to X c À as this drug also inhibits Nf-kB activation (Chung et al., 2005) , the basis for the toxic effects observed remains speculative. Thus, more specific X c À inhibitors might be considered for further structure-relationship studies and preclinical data warrant the development of more potent and selective system X c À inhibitors. Monolayer culture Human (U87-MG, U373-MG), rat (F98, C6) and mouse glioma cell lines (GL-261, SMA-560) were cultivated as described (Eyupoglu et al., 2005a) Cell proliferation and cytotoxicity assays Cell proliferation was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium-bromide (MTT) assay as described previously (Eyupoglu et al., 2005a) . Briefly, glioma cells were seeded into 96-well plates (5000 cells per well; total volume 300 ml per well), treated with the test compound or solvent and analyzed after 96 h. Lactate dehydrogenase, a cytosolic enzyme that is released from the cell upon loss of plasma membrane integrity, was measured using the CytoTox 96 Assay (Promega, Madison, WI, USA) according to the manufacturer's protocol (5000 cells per well using 96-well plates, 96 h). For all assays, each experiment was repeated at least eight times (n ¼ 8). Signals were quantified using a Tecan Safire 2 microplate reader (Tecan, Zurich, Switzerland).
Materials and methods

Chemicals
RNA isolation, RT-PCR and analysis of GluR2 flip/flop splicing and Q/R mRNA editing RNA isolation was performed using the RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA concentrations were determined using a NanoDrop ND-1000 spectrophotometer (Peqlab, Erlangen, Germany). For nonquantitative analyses, reverse transcription (RT) was performed using oligo dT primers and 1 mg of total RNA by applying the SuperScript First-Strand Synthesis System (Invitrogen). 2 ml of each 20 ml RT reaction was used for each RT-PCR. The following primer pairs were used for the analyses of GluR2 flip/flop splicing and GluR2 Q/R editing: GluR2_flip/flop_fwd: CCTACACGGCT AACTTAGC, GluR2_flip GluR2 flip/flop and Q/R isoforms were discriminated using restriction site assays. MspA1I (R0577; New England Biolabs) cleaves the GluR2 flop isoform (2 h incubation). Bbv1 (R0173; New England Biolabs) cleaves the Q/R unedited GluR2 isoform (16 h incubation), whereas AciI (R0551; New England Biolabs) cleaves the Q/R edited GluR2 isoform (16 h incubation). GluR2 Q/R editing was further assessed by pyrosequencing. Amplification of the GluR2 cDNA region containing the Q/R editing site was performed as described above using a biotinylated reverse primer. The biotinylated PCR products (25 ml) were cleaned up using Streptavidin Sepharose High Performance (GE Healthcare, Uppsala, Sweden) and a PyroMark Vacuum Prep Workstation (Biotage, Uppsala, Sweden). ) was used to calculate the expression levels of each target gene relative to time-and solvent-matched controls. The RT-PCR specificity was verified by melting curve analysis. The following primers were used for quantification of the GluR1, GluR2, GluR3 and GluR4 transcript expression levels in mouse (SMA-560, GL-261), rat (F98, C6), human (U87-MG, U373-MG) glioma cell lines and rat primary astrocytes (m ¼ mouse, r ¼ rat, h ¼ human): m/r/h_GluR1_fwd: TGGTTGCCTTAATCGAG TTCTGC, r_GluR1_rev: GCTCCTGCCCCACTGTTC, m/h_ GluR1_rev: CTCCTGCCCCGCTGTTS; m/r/h_GluR2_fwd: GCARGGATGCGATATTTCGCC, m/r/h_GluR2_rev: CTA CAGTCAGGAAGGCAGCT; m/r/h_GluR3_fwd: GGSCTG GCCATGATGGTG, m/r/h_GluR3_rev: CTCTGTATGTAG CRTAATTCTGAG; m/r/h_GluR4_fwd: GCAAYGTAGCA GGCGTCTTC, m/r/h_GluR4_rev: CATTCTCTTCGCYTC TGCCC. Analyses of xCT transcript levels were performed as described previously (Savaskan et al., 2008) . Real-time RT-PCR was conducted with four technical repetitions (n ¼ 4) for each gene and each RNA sample.
Glioma cell transfection
Transfection of the pEGFP-N1 expression vector (Clontech, Heidelberg, Germany) into F98 glioma cells was performed as described (Eyupoglu et al., 2005a, b) . Transfected cells were cultured in selection medium containing 500 mg G418/ml (SigmaAldrich). Stably xCT or scrambled siRNA expressing F98 rat glioma cells were transfectionally generated as previously described (Savaskan et al., 2008) . Glutamate estimation was performed using a Waters 600S HPLC (Waters GmbH, Eschborn, Germany) as described earlier (Savaskan et al., 2008) .
Organotypic glioma invasion model and primary cell cultures
Brain slices were prepared and maintained according to the interface technique as described in detail (Eyupoglu et al., 2005a) . In brief, 7-day-old Wistar rats were decapitated, the brains were rapidly removed and placed into ice-cold preparation medium. After dissection of the frontal pole of the hemispheres and the cerebellum, the brains were cut in 350 mm thick horizontal slices using a vibratome (Leica VT 1000S; Leica, Bensheim, Germany) in preparation medium. Brain slices were transferred onto culture plate insert membranes (Becton Dickinson, Franklin Lakes, NJ, USA; 0.4 mm pore diameter) and subsequently into six-well culture dishes containing 1.2 ml OHSC medium (Eyupoglu et al., 2005a) . The medium was changed 1 day after preparation and every second day thereafter. A total of 5000 GFP-positive F98 glioma cells were implanted within a total volume of 0.1 ml medium into the entorhinal cortex 1 day after slice preparation (Eyupoglu et al., 2005a (Eyupoglu et al., , 2006 . One day after implantation and every following day, glioma growth and invasion were evaluated using a fluorescence microscope as described below. At least five brain slices were used for each experiment (n ¼ 5). At DAI 5, slice cultures were incubated with 1 mg/ml PI for 20 min followed by complete medium change to visualize irreversibly damaged cell bodies. For immunocytochemistry, brain tissue was fixed in 4% paraformaldehyde as described and cryopreserved in 30% sucrose. Subsequent immunostaining was performed with neuronal marker NeuN (purchased from Chemicon, Hants, UK) and for counterstaining Hoechst (Sigma-Aldrich) was applied according to the supplier. Primary astrocytes were isolated as described (Savaskan et al., 2007) . Briefly, astrocytes were prepared from postnatal rat cerebrum aged P1-P3. Meninges were carefully removed and the cerebrum was gently homogenized with fire-polished Pasteur pipettes and subsequently incubated with trypsin/ DNase (1.25%/2 U). Dissociated astrocytes were plated on poly-L-lysine-coated dishes and cultured in DMEM containing 4.5 g/l glucose, 200 mM glutamine, pyruvate, 10% FCS and 100 U/ml penicillin/streptomycin.
Microscopical evaluation
Morphometrical analyses were performed using high-power optical fields digitized with a CCD camera (Color View II; Soft Imaging System, Muenster, Germany) equipped with a BX51 microscope (Olympus, Hamburg, Germany) using analySIS documentation software (Soft Imaging System). Fluorescence (eGFP)-labeled tumor cells transplanted into brain tissue as well as PI staining intensities were analyzed by an Olympus IX70 microscope equipped with a TRITC (excitation filter 520-550 nm, barrier filter 580 nm) and FITC (excitation filter 450-490 nm, band filter 520-550) narrow band filter and a CCD camera (F-View II; Soft Imaging System).
Data analysis
Concentration-effect curves were analyzed by nonlinear regression analysis (GraphPad software 5.03; GraphPad, San Diego, CA, USA) as described (Eyupoglu et al., 2005a) , by applying a four-parameter logistic equation containing the parameters top plateau, bottom plateau, inflection point (IC 50 ) and curve slope. Drug concentrations inducing a 50% reduction of cell growth were read from the best-fit curves. For statistical analysis, single comparisons were analyzed by unpaired t-tests, whereas multiple comparisons among the data sets were performed by two-way analysis of variance (GraphPad Prism). Three levels of statistical significance were discriminated (*Po0.05, **Po0.01, ***Po0.001).
